Review article: stem cell therapy in orthopaedic surgery: current status and ethical considerations by Hui, J.H.P. et al.
4ABSTRACT
Regenerative medicine using stem cell therapy has sparked
much interest in this 21st century not only because of the
controversies that surround the ethics involving pluripotent
stem cells but their potential for use in the clinic. The ability of
stem cells to repair and regenerate new tissues and organs holds
tremendous promise for the treatment of many serious diseases
and injuries.  This review provides a brief summary of the
current status of research in stem cells with special emphasis on
where we are in terms of the possible clinical application of
stem cell therapy in orthopaedic surgery. We look at the
available evidence and examine the ethical issues and
considerations associated with the clinical use of stem cells. 
WHAT ARE STEM CELLS
Stem cells have the capacity for self-renewal and the ability
to differentiate into various types of tissues under certain
conditions. Stem cells are classified based on their source
into embryonic stem cells (ESCs), foetal stem cells (FSCs),
and adult stem cells. Pluripotent ESCs are capable of
differentiating into any tissue type.  Adult stem cells are
much more limited in their regenerative capability and are
usually restricted to the tissues they reside in (i.e., liver
hepatocytes and haemopoietic stem cells) (Figures 1 and 2). 
It is currently highly risky to use ESCs in the clinic, as the
issues of teratogenicity and immune reaction by the recipient
have not been fully resolved. One technique for reducing the
possibility of teratoma formation is to convert the pluripotent
ESCs to multipotent mesenchymal stem cells (MSCs) 1.  The
concern about immunogenicity has resulted in the quest for
personalised pluripotent stem cells. In this regard, patient-
specific cell lines have been developed by reprogramming
adult cells to an embryonic state utilizing somatic cell
nuclear transfer techniques (SCNT). More recently,
Takahashi and Yamanaka have been able to create a
pluripotent stem cell (iPSC) by the insertion of four
transcription factors (Oct4, Klf4, Sox2 and c-Myc) into
mouse skin fibroblasts 2. Although these cells would be
autologous and presumably non-immunogenic, there are still
many potential problems as the induction is performed with
viral vectors and the issue of teratogenesis still remains.
In the field of Orthopaedics, autologous stem cells such as
mesenchymal stem cells (MSCs) are readily available and are
amenable to harvesting and isolation from the bone marrow
and other tissues of mesodermal origin. MSCs are already
pre-programmed to differentiate into musculoskeletal tissue
types. The challenge would be to expand them in adequate
numbers and ensure that they are able to differentiate into the
correct phenotype of tissue that they are intended to repair.
ORTHOPAEDIC APPLICATIONS OF STEM CELL
THERAPY
The challenge in orthopaedics is to repair and regenerate
damaged or diseased musculoskeletal tissues. The most
commonly used stem cells are MSCs. These are non-
hematopoietic, stromal cells that exhibit multilineage
differentiation capacity, and are able to give rise to diverse
tissues, including bone, cartilage, adipose tissue, tendon and
muscle. These cells can be isolated from bone marrow or
obtained under culture from various other sources, such as the
periosteum, fat and skin 3.  Under controlled conditions, these
cells can differentiate into multi-mesenchymal lineage (such
as osteoblast, chondrocyte and adipocyte) and myoblast
lineages, making them useful for cell and tissue engineering
as well as gene therapy for Orthopaedic applications.
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Cartilage
Injured articular cartilage has poor potential for repair due to
its avascular nature. Chondral damage is potentially a major
cause of joint disease and disability as it can lead to
osteoarthritis (OA), and it is well known that cartilage rarely
heals spontaneously 4-9. Procedures involving penetration of
subchondral bone for traumatic chondral defects or
ostechondritis dissecans, eventually produce healing due to
the presence of fibrocartilage tissue and may give rise to
good short to intermediate term results 10,11.  Fibrocartilage
arising due to these techniques has poor mechanical
properties compared to normal cartilage. Autologous
chondrocyte implantation (ACI) is a biological attempt to
regenerate normal articular cartilage. 
While these techniques in biological resurfacing of cartilage
defects require an open arthrotomy or arthroscopy, Lee et al
investigated the possibility of direct intra-articular injection
of MSCs suspended in hyaluronic acid (HA) as an alternative
method. A partial-thickness cartilage defect was created in
the medial femoral condyle of an adult minipig. MSCs
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cultured from the iliac crest marrow of the same pig
harvested and isolated in a separate procedure and suspended
in 2 millilitres of hylan G-F 20 (Synvisc) were injected three
times at weekly intervals intra-articularly after the creation of
the defect. The cell-treated the pigs that received MSCs in
HA showed improved cartilage healing both histologically
and morphologically at 6 and 12 weeks compared with the
controls 12.  In another study, Wakitani et al studied the
effectiveness of autologous cultured bone marrow MSC
transplantation in nine full-thickness articular cartilage
defects of the patello-femoral joints (including two kissing
lesions) in the knees of three patients. Six months after
transplantation, the patients' clinical symptoms had improved
and the improvements have been maintained over the follow-
up periods (17-27 months) 13. 
A recent study investigated the feasibility of using
autologous uncultured bone marrow-derived mononuclear
cell transplantation in large full-thickness cartilage
regeneration in 48 rabbits 14.  The animals were divided into
four groups: autologous uncultured bone marrow-derived
mononuclear cells with fibrin gel (BMC), autologous
uncultured peripheral blood-derived mononuclear cells with
fibrin gel (PBC), fibrin gel alone (GEL), or nothing (CON)
All cell group types were transplanted to the articular
cavities of the rabbits seven days after the initial operation.
Histological, histochemical grading and safranin O staining
were used to evaluate the results. The BMC group was found
to have superior cartilage repair compared to the other
groups, and the PBC and CON showed  similar inferior
results, but were still slightly better than did the GEL group.
Therefore, it was concluded that transplantation of
autologous uncultured bone marrow-derived mononuclear
cells contributes to articular cartilage repair has clinical
potential. It is worthwhile to note that in this study the
autologous uncultured peripheral blood-derived
mononuclear cells showed inferior results when compared to
the bone marrow-derived mononuclear cell group.
Bone
MSCs can be used to enhance bone regeneration and union
in cases of critical bone defect, non-union, physis
regeneration in children and to improve bone quality in
osteogenesis imperfecta. For non-union cases, even though
iliac crest bone grafts are still considered to be the gold
standard due to their osteogenic, osteoinductive and
osteoconductive properties 15, loading MSCs on an injectable
carrier have been tested for efficacy as an alternative for
open surgical procedures 16,17.  The simple, minimally invasive
technique of percutaneous bone marrow grafting in patients
suffering from tibial nonunion has been shown to result in
union for most patients 18.
In critical bone defect there is loss of a portion of bone that
then fails to heal and requires bone reconstruction to prevent
a non-union. MSCs could facilitate osteogenesis in these
settings, if loaded in scaffolds of predefined dimensions and
shape to fit in the defect 19.  Quarto et al. used autologous
MSCs in a porous ceramic scaffold to treat segmental bone
defects in a limited group of patients for whom a traditional
therapeutic alternative was very difficult or had already
failed 20.  Human adipose tissue-derived MSCs 21 and muscle-
derived MSCs have also been described as a source of
osteoproductive cells for improved healing of critical bone
defects 22.  
Physeal injury in a growing child often results in formation
of bony bridges that eventually lead to angular deformities or
shortening. For angular deformities, various types of
hemiepiphysiodeses can be used in skeletally immature
patients, including stapling, percutaneous epiphysiodesis or
the use of eight plates. For a skeletally mature adolescent,
osteotomy can be considered. Excision of bony bridges and
insertion of fat 23, polymeric silicone 24 or muscle 25 have been
described to prevent bony bridges from reforming. However,
these interposition techniques are only useful when the bony
bridge is small (<30%). More recently, cultured autologous
chondrocytes 26-28 and MSCs from bone marrow have been
shown to repair large physeal defects leading to significant
reduction in growth arrest 29,30. 
Osteogenesis imperfecta (OI) is a genetic disorder caused by
defects in type I collagen. Ideally, the treatment of OI should
be directed toward enhancing bone strength by improving the
structural integrity of collagen 31.  Pereira et al. infused bone
marrow-derived MSCs from a normal mouse into irradiated
transgenic recipient mice with an OI phenotype. Several
months after transplantation the recipient mice demonstrated
the presence of donor-derived MSCs in various organs,
including bone, cartilage, lung and spleen. MSCs that homed
to the bones differentiated into osteocytes and produced
normal levels of collagen type I, with partial ablation of the
Osteogenesis Imperfecta phenotype 32. Similar results have
been obtained after allogenic bone marrow transplantation in
patients with OI. [33] MSCs transferred in a bone marrow
graft may play a potential role in the cure for OI.
Tendons and Ligaments
Once injured, tendons and ligaments produce inferior quality
repair tissue due to their limited regenerative ability. Use of
biological grafts such as autografts, allografts and resorbable
biomaterials can result various complications such as donor
site morbidity, scar formation, risk of infection and tissue
rejection. Thus, a biological solution using MSCs to
regenerate tissues similar to the tissue of origin has attracted
the interest of researchers in this field. Application of a
collagen gel loaded with MSCs in a rabbit achilles and
patellar tendon defect resulted in improvement of structure,
biomechanics, and function 34,35. 
Another challenging issue is the healing of the tendon graft
to the bone (graft-host junction) in instances such as anterior
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cruciate ligament reconstruction. The normal anatomy of the
insertion site of the ACL is fibrocartilaginous tissue that has
complex anatomy. Conventional free tendon transfers are
unable to restore this complex anatomy within the first six
months 36. Rodeo et al showed that BMP-2 can augment
tendon healing in a bone tunnel 37.  Lim et al studied the role
of MSCs at the tendon-bone junction during reconstruction
of the ACL in the rabbit and showed that applying MSCs to
tendon grafts at the tendon-bone junction results in a zone of
fibrocartilage at the junction which more closely resembled
that of the normal ACL. These enhanced grafts have
improved biomechanical properties compared to controls,
and have exhibited a rapid and significant increase in load to
failure and stiffness in the first eight weeks after ACL
reconstruction 38.  Another recent study saw the use of
synovial MSCs in the insertion of the Achilles tendon graft
of rats into a bone tunnel from the tibial plateau to the tibial
tuberosity. It was observed histologically that implantation of
synovial MSCs into the bone tunnel accelerated healing and
showed early remodeling of tendon-bone junction 39.
Meniscus
Injury to the inner third of the meniscus has limited healing
potential due to its avascular nature. Meniscal repair is not
possible in the avascular portion and meniscectomy has been
shown to have a strong association with the subsequent
development of osteoarthritis. This has led to investigations
into the possibility of cell-based meniscal repair and
regeneration.  It has been demonstrated that isolated
chondrocytes seeded on to meniscal matrices were able to
bond separate pieces together. Histological and
biomechanical analyses showed that the strength of the
adhesion increased over time by the formation of a newly
synthesised cartilaginous matrix 40. Meniscal repair following
intra-articular injection of MSCs has also shown
improvement in meniscal wound healing; even in avascular
areas, there was production of an abundant extracellular
matrix contributed to meniscal repair 41,42.
A recent study tested a cell-scaffold combination for the
repair of a critical-size defect of the rabbit medial meniscus 43,
by compaing a hyaluronan/gelatin composite scaffold, and
also scaffolds loaded with autologous marrow-derived
MSCs, and empty scaffolds in the contralateral knees to
untreated contralateral defect as control. Untreated defects
had a muted fibrous healing response. Pre-cultured implants
integrated with the host tissue and eight of 11 contained
meniscus-like fibrocartilage, compared with two of 11
controls (p < 0.03). The mean cross-sectional width of the
pre-cultured implant repair tissue was greater than controls
(p < 0.004). This study demonstrated that repair of a critical
size meniscal defect with a stem cell and scaffold based
tissue engineering approach is a potential clinical application
of MSCs 43.
Centeno et al conducted a study to determine if isolated and
expanded human autologous MSCs could effectively
regenerate cartilage and meniscal tissue when
percutaneously injected into knees 44. MSCs isolated from
bone marrow aspiration of the iliac crest of a consenting
volunteer were cultured ex-vivo and percutaneously injected
into the subject’s knee with MRI proven degenerative joint
disease. At 24 weeks post-injection, the subject had
statistically significant cartilage and meniscus growth on
MRI, as well as increased range of motion and decreased
modified VAS (visual analogue scale) pain scores. This has
significant future implications for minimally invasive
treatment of osteoarthritis and meniscal injury 44.
Muscles and Skin
Injured muscle fibres produce signals to promote myogenic
differentiation [45] and drive MSCs to occupy the damaged
area and regenerate damaged fibres 46. In Duchenne Muscular
Dystrophy (DMD), which is characterized by progressive
muscular weakness and muscle wasting eventually leading to
paralysis and death, intravenous injection of MSCs in models
of immunodeficient mice with DMD has shown
differentiation of MSCs into muscle fibres and partial
restoration of dystrophin expression 47. However, clinical
applications require further advances in cell engineering and
gene therapy. In the autologous transplantation of muscle-
derived CD133+ cells in a 7-month, double-blind phase I
clinical trial conducted on 8 boys with DMD, patients
showed an increased ratio of capillary per muscle fibers with
a switch from slow to fast myosin-positive myofibres 48.
MSCs have also been investigated for the treatment of
chronic skin wounds 49. Three patients suffering from chronic
skin wounds of more than one year duration that did not
respond to bioengineered skin applications or skin grafting
with autologous skin were treated with application of
autologous bone marrow-derived MSCs. In all three patients,
complete wound closure was observed 49.
Spine, Spinal Cord and Neural Tissues
Repair of the spinal cord is a very complex process that
includes restoring or enhancing local spinal reflex arcs and
reconnecting regenerating axons 31.  Evidence of axonal
regeneration and functional recovery has been seen in animal
models of spinal cord injury. Akiyama et al have
demonstrated that MSCs isolated in culture from the
mononuclear layer of bone marrow can remyelinate
demyelinated spinal cord axons after direct injection into the
lesion. However, stem cells alone may not be enough to
improve function in a damaged spinal cord 50.
Rosenfeld and Gillett have recently discussed problems
associated with the use of stem cells in this context and
cautioned against premature application of this technology.
They warned against extrapolating the results of animal
experiments directly to humans, as there may be a risk of
further morbidity and even tumour growth 51.  Strategies for
repair of the human spinal cord will, of necessity, be
multifaceted, entailing enhancement of axonal growth and
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reconnection, replacement of cellular elements, and the
reversal of demyelination as necessary steps for success. The
connective tissue matrix, the degree of glial scarring and the
central myelin inhibitory factors, the elimination of which is
required for axon outgrowth, are all important. The balance
of these factors may be as important as the stem cells
themselves, and very difficult to optimise 51.
Intervertebral disc degeneration, which is manifested by
gradual loss of water and proteoglycans, can lead to back
pain and other morbidity. Treated conservatively,
approximately 90% of patients show improvement. After
failure of conservative treatment, surgical options can be
considered. Cell-based tissue engineering offers considerable
promise for a biological alternative (transplantation to the
intervertebral disc of mature autologous disc cells,
chondrocytes or stem cells). Cell transplantation can
potentially increase proteoglycan production, induce disc
regeneration or slow the process of degeneration. In animal
models, transplantation of autologous disc cells and
chondrocytes derived from costal cartilage has been
demonstrated to be feasible and may slow disc degeneration 52.
MSCs may potentially also contribute to the repair of
peripheral nerves due to their ability to differentiate into
neurons and glia 53. Regeneration, functional recovery and
healing of transected sciatic nerve has been demonstrated in
several animal models 54.
ETHICAL CONSIDERATIONS
While prohibition of reproductive cloning is generally
accepted, there is wide variability amongst different
countries regarding the ethical guidelines and regulation of
stem cell research and therapy. Recognising that these
differences are inevitable, the International Stem Cell Forum
(ISCF) was initiated in 2002 by Sir George Radda who was
then the Chief Executive of the Medical Research Council
(MRC) of the United Kingdom. The ICSF consists of
delegates representing the funding agencies of countries
involved in stem cell research. The aims of the ISCF are
primarily designed to forge international collaborations in
stem cell research by working to establish the standardisation
of techniques, the sharing of cell lines, training, conferences,
and information. Various subcommittees have been
organised to discuss scientific issues, ethics and intellectual
property.
In a similar vein, the International Society for Stem Cell
Research (ISSCR) is a society for scientists involved in stem
cell research. In addition to the publication of the Guidelines
for the Conduct of Human Embryonic Stem Cell Research in
December 2006, the ISSCR recently published its Guidelines
for the Clinical Translation of Stem Cells, which is available
online at http://www.isscr.org/clinical_trans/index.cfm 55.
These guidelines were developed by the Task Force for the
Clinical Translation of Stem Cells, a multidisciplinary group
of stem cell researchers, clinicians, ethicists, and regulatory
officials from 13 countries. They highlight the scientific,
clinical, regulatory, ethical, and social issues that should be
addressed so that basic stem cell research is responsibly
translated into appropriate clinical applications for treating
patients. The Guidelines pertain to clinical translational
research involving products from human embryonic or other
pluripotent stem cells, novel applications of foetal or somatic
(adult) stem cells, and hematopoietic or other stem cells used
for applications outside established standards of care. The
Guidelines address three major areas of translational stem
cell research: (a) cell processing and manufacture; (b)
preclinical studies; and (c) clinical research 55.  The ISSCR
also provides information for patients and their doctors
evaluating stem cell therapy in its Patient Handbook on Stem
Cell Therapies 56. These publications are very important
guides and are highly recommended as reading material for
those interested in using stem cells for therapeutic purposes.
While stem cell research holds tremendous promise for the
development of new treatments for many serious diseases,
nearly all stem cell therapies are new and highly
experimental. Therefore, there is an urgent need to address
the problem of unproven stem cell therapies being marketed
directly to patients. Unfortunately, there are clinics around
the world that exploit patients’ hopes by offering “stem cell
therapies”, without credible scientific rationale, oversight or
any form of patient protection. Lau et al analyzed websites in
which stem cell clinics advertise via internet and appraised
the relevant published clinical evidence of stem cell therapies
to address three questions about these direct-to-consumer
portrayals of stem cell medicine in this early market: i)What
sorts of therapies are being offered?; ii) How are they
portrayed?; and, iii) Is there clinical evidence to support the
use of these therapies? Overall, they found that the portrayal
of stem cell medicine on provider websites is optimistic and
unsubstantiated by peer-reviewed literature 57.
CURRENT STATUS OF STEM CELL THERAPY
“Stem Cells: Hype or Hope?” Given the amount of hype that
the media (and especially the internet) has given to stem cells
as a cure for diseases that hitherto have not been successfully
treated, it is the responsibility of every doctor to ensure that
he/she has enough knowledge of the current status of stem
cell therapies so that he/she can correctly advise his/her
patient.  At this time, it is fair to say that the research on
ESCs and iPSCs is still fairly upstream and there should not
be any attempt made to use these cells to treat
musculoskeletal problems in patients. Both types of
pluripotent cells share similar problems of possible
teratogenicity which must resolved before these cells can be
safely used in a clinical setting. Although there have been
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attempts to reduce the possibility of teratoma formation by
using MSCs derived from hESCs, this technique is still at the
pre-clinical stage of research.
In general the use of adult stem cells is closer to the clinic as
these cells are less potent than ESCs and more directed, so
there is little or no likelihood of teratoma formation. There
are now many pre-clinical studies in animals as well as a few
clinical studies using bone marrow-derived MSCs to treat
musculoskeletal problems. Most of these studies show
promising results and are fairly safe as autologous cells are
used. Bone marrow-derived MSCs have also been shown to
be more directed towards forming cartilage than fat-derived
MSCs, suggesting that these stem cells are pre-programmed
to form certain tissues more efficiently than others 58.  Some
studies have also shown that allogeneic MSCs do not evoke
an immune response so there is potential for the use of
allogeneic MSCs in the future 59.  
The role of other stem cells in musculoskeletal regenerative
medicine has not been as well investigated. Cord blood is
generally used for haemopoietic disorders and has not been
shown conclusively to be useful in the regeneration of
musculoskeletal tissues. There are extremely few stem cells
in peripheral blood and the use of peripheral blood for
cartilage repair has been shown to be inferior to that of bone
marrow-derived cells 14.  Similarly, aspirated bone marrow
(without any further manipulation) has very few stem cells
and is unlikely to produce any significant healing in cartilage
or tendon defects.
When using stem cells in a clinical situation, it is very
important that the cells have been derived and expanded
under strict cGMP conditions. Informed consent must be
obtained and the patient has to be followed closely to ensure
his/her safety after stem cell transplantation. The ISSCR
Guidelines for the Clinical Translation for Stem Cells and the
Patient Handbook on Stem Cell Therapies provide the
requisite information for the clinical use of stem cells 55,56.
Finally, it is important to note that as a doctor, the patient’s
safety and well-being must always come first. As pointed out
by Lau et al 57, many of the advertised stem cell treatments on
the Internet are not evidence-based. Patients must be
protected from exploitation by such unscrupulous practices. 
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